Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

Cocky_day_trader Feb. 3 at 9:17 PM

$GRI yes yes come come. At least $3

1 · Reply

Cocky_day_trader Feb. 3 at 9:12 PM

$GRI yes yes come up.

0 · Reply

Cocky_day_trader Feb. 3 at 9:07 PM

$GRI Come up quick I need to dump and exit

0 · Reply

Cocky_day_trader Feb. 3 at 9:02 PM

$GRI Is it going up Come baby man wants exit asap

0 · Reply

Schizoo Feb. 3 at 8:19 PM

$GRI it it time to pump this? Short interest is really high..

1 · Reply

abc12379593827 Feb. 3 at 7:58 PM

$GRI the vast majority of retail doesn’t care about the companies we buy. We’re not here for dividends, don’t attend meetings, and don’t even really care about what the company does. We are here only for violent spikes up and sell on same day or shortly thereafter. This has all the ingredients for that. This stock went from about 5 to 12 in 30 seconds. I know because I made 4k in ten seconds that day. It can and will do it again, except the base is not around 2.8.

1 · Reply

Sedmica82 Feb. 3 at 7:56 PM

$GRI

0 · Reply

Qwrtyu Feb. 3 at 7:47 PM

$GRI

0 · Reply

Sedmica82 Feb. 3 at 7:11 PM

$GRI

0 · Reply

Cocky_day_trader Feb. 3 at 6:24 PM

$GRI all my followers who made bank agreed that one is better at cash management and the other is toxic who hires Wainwright One deserves a medal and the other diserves the man below

0 · Reply

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Jan 21, 2026, 4:01 PM EST - 13 days ago

GRI Bio Announces Reverse Stock Split

Dec 12, 2025, 4:05 PM EST - 7 weeks ago

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 7 weeks ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 10, 2025, 4:05 PM EST - 7 weeks ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 5 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Aug 14, 2025, 9:15 AM EDT - 6 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 6 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 22, 2025, 8:45 AM EDT - 7 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:45 AM EDT - 7 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 7 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 9:15 AM EDT - 9 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 16, 2025, 9:15 AM EDT - 9 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 15, 2025, 8:35 AM EDT - 9 months ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 8, 2025, 8:45 AM EDT - 9 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 9 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 10 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 10 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 11 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:07 AM EDT - 11 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Mar 31, 2025, 8:00 AM EDT - 11 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 18, 2025, 9:05 AM EDT - 11 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 11 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 11, 2025, 8:35 AM EDT - 11 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Cocky_day_trader Feb. 3 at 9:17 PM

$GRI yes yes come come. At least $3

1 · Reply

Cocky_day_trader Feb. 3 at 9:12 PM

$GRI yes yes come up.

0 · Reply

Cocky_day_trader Feb. 3 at 9:07 PM

$GRI Come up quick I need to dump and exit

0 · Reply

Cocky_day_trader Feb. 3 at 9:02 PM

$GRI Is it going up Come baby man wants exit asap

0 · Reply

Schizoo Feb. 3 at 8:19 PM

$GRI it it time to pump this? Short interest is really high..

1 · Reply

abc12379593827 Feb. 3 at 7:58 PM

1 · Reply

Sedmica82 Feb. 3 at 7:56 PM

$GRI

0 · Reply

Qwrtyu Feb. 3 at 7:47 PM

$GRI

0 · Reply

Sedmica82 Feb. 3 at 7:11 PM

$GRI

0 · Reply

Cocky_day_trader Feb. 3 at 6:24 PM

$GRI all my followers who made bank agreed that one is better at cash management and the other is toxic who hires Wainwright One deserves a medal and the other diserves the man below

0 · Reply

dButterz Feb. 3 at 5:37 PM

$GRI leave a comment and let them know what a great job they are doing... https://ir.stockpr.com/tonixpharma/sec-filings-email/content/0001999371-26-002429/tonix-8k_020326.htm

1 · Reply

Sedmica82 Feb. 3 at 5:27 PM

$GRI Bull shit

0 · Reply

gregwiseman Feb. 3 at 5:26 PM

$GRI in the next reverse split all the previous shareholders will be wiped away so no more retail shareholders will be here . Unless other reckless dumb investors will get fooled once again

0 · Reply